Welcome to our dedicated page for Eyenovia news (Ticker: EYEN), a resource for investors and traders seeking the latest updates and insights on Eyenovia stock.
Eyenovia Inc (EYEN) is a clinical-stage biopharmaceutical innovator advancing precision ophthalmic therapies through its proprietary microdosing technology. This page serves as the definitive source for verified company news, including clinical trial milestones, regulatory updates, and strategic partnerships shaping the future of eye care.
Investors and industry professionals will find timely updates on key initiatives such as Optejet delivery system advancements, pipeline developments for mydriasis and myopia treatments, and commercialization progress. Our curated news collection ensures transparent access to material events impacting Eyenovia's position in the ophthalmic therapeutics market.
Content highlights include FDA submission announcements, partnership agreements with healthcare providers, research publications, and financial performance updates. All information is sourced directly from official company communications to maintain accuracy and compliance.
Bookmark this page for streamlined access to Eyenovia's latest developments in microdose array print (MAP) technology and its application in improving ocular treatment outcomes. Regularly updated to reflect the evolving landscape of precision ophthalmology.
Eyenovia, Inc. (NASDAQ: EYEN) announced upcoming presentations on their clinical trials at the American Academy of Optometry Academy 2020 event. Dr. April Jasper will present updates on the CHAPERONE and VISION studies, focusing on low-dose atropine and pilocarpine for myopia and near vision improvement, respectively. Dr. Siddarth Rathi will discuss results from the MIST studies, evaluating a microdose formulation for pupil dilation. Eyenovia's innovative microdose array print (MAP™) therapeutics aim to enhance treatment efficacy for various ophthalmic conditions.
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company, will present at the 22nd Annual H.C. Wainwright Global Investment Conference from September 14-16, 2020. The presentation will be delivered by Dr. Sean Ianchulev, CEO, and John Gandolfo, CFO, on September 15, 2020, from 2:30 to 2:50 PM ET. Eyenovia focuses on developing microdose array print (MAP™) therapeutics targeting presbyopia, myopia progression, and mydriasis. For more details, visit www.eyenovia.com.
Eyenovia, Inc. (NASDAQ: EYEN) announced the successful closing of an underwritten public offering of 3,333,334 shares at $3.60 per share, raising approximately $10.9 million in net proceeds. The funds will be utilized for the clinical development of product candidates, initial commercialization of MicroStat, and general corporate purposes. The offering was conducted under a shelf registration statement effective since February 12, 2019. William Blair & Company served as the book-running manager, with National Securities Corporation as the co-manager.
Eyenovia, Inc. (NASDAQ: EYEN) announced the pricing of a public offering of 3,333,334 shares at $3.60 each, expected to close on August 21, 2020. The offering could yield around $12 million in gross proceeds, intended for clinical development, MicroStat commercialization, and general corporate purposes. Underwriters have a 30-day option to purchase an additional 500,000 shares. This offering is made under an SEC shelf registration statement effective since February 2019.
Eyenovia, Inc. (NASDAQ: EYEN) announced plans to offer common stock in an underwritten public offering, with a potential 30-day option for the underwriter to purchase an additional 15% of the shares. The offering is contingent on market conditions, and there is no guarantee regarding its completion or terms. Proceeds will support clinical development of its therapeutics, initial commercialization of MicroStat, and general corporate needs. William Blair & Company acts as the sole book-running manager, and the offering will be conducted under an effective shelf registration statement.
Eyenovia, Inc. (NASDAQ: EYEN) announced its financial results for Q2 2020, reporting a net loss of approximately $5.0 million, or $(0.25) per share, which is an improvement from a net loss of $5.3 million, or $(0.44) per share in Q2 2019. Research and development expenses decreased by 18.3% to around $2.9 million. The company announced an exclusive licensing agreement with Arctic Vision to commercialize MicroPine and MicroLine in Greater China and South Korea, with potential payments of up to $45.75 million. Eyenovia plans to submit its New Drug Application for MicroStat by the end of 2020.
Eyenovia, Inc. (NASDAQ: EYEN) has resumed patient enrollment for its Phase III CHAPERONE study targeting progressive myopia in children, halted due to the COVID-19 pandemic. The study aims to determine the efficacy of MicroPine, an atropine ophthalmic solution, in reducing myopia progression among over 400 participants aged 3-12. The primary endpoint is a <0.5 D increase in refractive error over 36 months. The company has continued monitoring previously enrolled patients remotely, ensuring steady progress.
Eyenovia, Inc. (NASDAQ: EYEN) has adjourned its 2020 Annual Meeting of Stockholders originally set for June 11 to June 30, 2020, to be held virtually. This transition allows stockholders, as of April 15, 2020, to participate remotely. They can listen, vote, and submit questions via live webcast. Stockholders are reminded that previously distributed proxy materials remain valid for voting. The company emphasizes the importance of pre-voting and participation in the meeting, available on the virtual meeting site.
Eyenovia, Inc. (NASDAQ: EYEN) has announced the adjournment of its 2020 Annual Meeting of Stockholders from June 11 to June 30, 2020, due to COVID-19 safety concerns. The meeting will transition to a virtual-only format, allowing stockholders and their proxies to participate remotely. Details for remote communication will be provided in a future press release and on Eyenovia's website. The company focuses on microdose therapeutics for eye conditions, using its unique piezo-print delivery technology.
Eyenovia, Inc. (NASDAQ: EYEN) reported its financial results for Q1 2020, highlighting a net loss of approximately $5.5 million, or $(0.31) per share, an improvement from a net loss of $(0.50) per share in Q1 2019. The company successfully raised around $5.4 million through a private placement. R&D expenses decreased by 9.3% to $3.6 million. However, the initiation of MicroLine Phase III studies is delayed due to the COVID-19 pandemic.
Eyenovia aims to submit a New Drug Application for MicroStat this year and resume clinical trials as conditions allow.